US EditionFirst participants recruited to bipolar depression study at Oxford Health NHS Foundation Trust | Oxford Health NHS Foundation Trust
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
First participants recruited to bipolar depression study at Oxford Health NHS Foundation Trust | Oxford Health NHS Foundation Trust
The ASCEnD study aims to address the limited treatment options available for people experiencing depressive symptoms associated with bipolar disorder. The study compares the clinical and cost effectiveness of a combination of two drugs, aripiprazole and sertraline, in comparison to quetiapine, a commonly prescribed treatment for people with bipolar disorder experiencing depression. Source
It is estimated that between 1 and 2.5% of the French population is affected by bipolar disorder. However, it takes an average of 7 to 10 years before receiving appropriate treatment and care. Why is this disorder so often confused with depression, and what are the risks for patients? Interview with Professor Raoul Belzeaux, psychiatrist at Montpellier University Hospital.
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
